Seelos Announces Postponement of its Annual Meeting of Stockholders
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has announced the postponement of its 2024 Annual Meeting of Stockholders. Originally scheduled for September 27, 2024, the meeting will now be held virtually on Friday, October 25, 2024, at 8:00 a.m. Eastern Time. The postponement is due to an anticipated lack of quorum and to allow more time for proxy solicitation.
The record date for the Annual Meeting remains August 19, 2024. Seelos' Board of Directors unanimously recommends voting FOR all Board nominees and proposals outlined in the company's proxy statement. Stockholders who have already voted do not need to take further action unless they wish to change their vote. Those who haven't voted are urged to do so before the postponed meeting.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ha annunciato il rinvio della sua Assemblea Annuale degli Azionisti 2024. Inizialmente programmata per il 27 settembre 2024, l'assemblea si terrà ora virtualmente venerdì 25 ottobre 2024, alle 8:00 ora orientale. Il rinvio è dovuto a una prevista mancanza di numero legale e per consentire più tempo per la sollecitazione delle deleghe.
La data di registrazione per l'Assemblea Annuale rimane 19 agosto 2024. Il Consiglio di Amministrazione di Seelos raccomanda unanime di votare a favore di tutti i candidati e delle proposte del Consiglio indicate nella dichiarazione di delega dell'azienda. Gli azionisti che hanno già votato non devono effettuare ulteriori azioni a meno che non desiderino modificare il loro voto. Coloro che non hanno votato sono invitati a farlo prima dell'assemblea rinviata.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) ha anunciado el aplazamiento de su Junta Anual de Accionistas 2024. Originalmente programada para el 27 de septiembre de 2024, la reunión se llevará a cabo ahora de manera virtual el viernes 25 de octubre de 2024, a las 8:00 a.m. hora del Este. El aplazamiento se debe a la falta anticipada de quórum y para permitir más tiempo para la solicitud de poderes.
La fecha de registro para la Junta Anual se mantiene en 19 de agosto de 2024. La Junta Directiva de Seelos recomienda unánimemente votar A FAVOR de todas las nominaciones y propuestas del Consejo que se detallan en la declaración de poder de la compañía. Los accionistas que ya han votado no necesitan tomar más acciones a menos que deseen cambiar su voto. Se insta a aquellos que no han votado a hacerlo antes de la reunión aplazada.
Seelos Therapeutics, Inc. (Nasdaq: SEEL)가 2024년 연례 주주총회의 연기를 발표했습니다. 원래 2024년 9월 27일로 예정되어 있었던 회의는 2024년 10월 25일 금요일 동부 표준시 기준 오전 8시에 가상으로 진행될 것입니다. 이번 연기는 예상되는 쿼럼 부족과 위임 solicitation을 위한 더 많은 시간을 허용하기 위함입니다.
연례 주주총회의 기준일은 2024년 8월 19일로 유지됩니다. Seelos의 이사회는 회사의 위임장에 설명된 모든 이사회 후보자 및 제안에 대해 찬성하는 투표를 만장일치로 권장합니다. 이미 투표한 주주들은 투표를 변경하고자 하지 않는 한 추가 조치를 취할 필요가 없습니다. 투표하지 않은 주주들은 연기된 회의 전에 투표할 것을 권장합니다.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) a annoncé le report de son Assemblée Annuelle des Actionnaires 2024. Initialement prévue le 27 septembre 2024, la réunion se tiendra désormais virtuellement le vendredi 25 octobre 2024, à 8h00 heure de l'Est. Ce report est dû à un quorum anticipé insuffisant et pour permettre plus de temps pour la sollicitation des procurations.
La date de référence pour l'Assemblée Annuelle reste le 19 août 2024. Le Conseil d'Administration de Seelos recommande à l'unanimité de voter POUR tous les candidats et propositions du Conseil indiqués dans la déclaration de procuration de l'entreprise. Les actionnaires ayant déjà voté n'ont pas besoin d'agir davantage à moins qu'ils souhaitent modifier leur vote. Ceux qui n'ont pas encore voté sont invités à le faire avant la réunion reportée.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) hat die Verschiebung seiner Jahresversammlung 2024 der Aktionäre angekündigt. Ursprünglich für den 27. September 2024 geplant, wird die Versammlung nun virtuell am Freitag, den 25. Oktober 2024, um 8:00 Uhr Eastern Time stattfinden. Die Verschiebung ist auf einen voraussichtlichen Mangel an Quorum und auf die Notwendigkeit zurückzuführen, mehr Zeit für die Proxysollicitation zu gewähren.
Das Stichtagsdatum für die Jahresversammlung bleibt der 19. August 2024. Der Vorstand von Seelos empfiehlt einstimmig, für alle Kandidaten und Vorschläge des Vorstands zu stimmen, die in der Proxydokumentation des Unternehmens aufgeführt sind. Aktionäre, die bereits abgestimmt haben, müssen keine weiteren Schritte unternehmen, es sei denn, sie möchten ihre Stimme ändern. Denjenigen, die noch nicht abgestimmt haben, wird geraten, dies vor der verschobenen Versammlung zu tun.
- None.
- None.
The Annual Meeting has been postponed due to an anticipated lack of quorum, and to provide further time to solicit proxies from the Company's stockholders. Seelos' Board of Directors unanimously recommends that you vote FOR the Board of Director nominees and FOR all other proposals identified in the Company's proxy statement for the Annual Meeting. Stockholders who have already cast their votes do not need to take any action, unless they wish to change or revoke their prior proxy or voting instructions, and their votes will be counted at the postponed Annual Meeting. For stockholders who have not yet cast their votes, we urge them to vote their shares now, so they can be tabulated prior to the postponed Annual Meeting.
About Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases.
For more information, please visit our website: https://seelostherapeutics.com, the content of which is not incorporated herein by reference.
IMPORTANT ADDITIONAL INFORMATION
Seelos has filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") on August 20, 2024. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY SEELOS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION. Stockholders may obtain a free copy of the proxy statement and the other relevant materials, and any other documents filed by Seelos with the SEC, at the SEC's web site at http://www.sec.gov or on the "SEC Filings" section of Seelos' website at https://seelostherapeutics.com.
Participants in the Solicitation
Seelos, its directors and executive officers and other members of management and employees will be participants in the solicitation of proxies with respect to a solicitation by Seelos. Information about Seelos' executive officers and directors, including information regarding the direct or indirect interests, by security holdings or otherwise, is available in Seelos' definitive proxy statement for its Annual Meeting, which was filed with the SEC on August 20, 2024. To the extent holdings by our directors and executive officers of Seelos securities reported in the proxy statement for the Annual Meeting have changed, such changes have been or will be reflected on Statements of Change in Ownership on Forms 3, 4 or 5 filed with the SEC. These documents are or will be available free of charge at the SEC's website at http://www.sec.gov.
Forward-Looking Statements
Statements made in this press release, which are not historical in nature, constitute forward-looking statements related to Seelos for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on Seelos' current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos' business and plans described herein include, but are not limited to, the risk of not receiving stockholder approval of any of the proposals to be presented at the Annual Meeting, the risks related to raising capital to fund its development plans and ongoing operations and risks related to Seelos' current stock price, as well as other risk factors and matters set forth in our periodic filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q, including Seelos' Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Contact Information:
Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue, 2nd Floor
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Mike Moyer
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401
(617) 308-4306
mmoyer@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-announces-postponement-of-its-annual-meeting-of-stockholders-302260282.html
SOURCE Seelos Therapeutics, Inc.
FAQ
When is the postponed Seelos Therapeutics (SEEL) Annual Meeting of Stockholders?
Why did Seelos Therapeutics (SEEL) postpone its 2024 Annual Meeting?
What is the record date for Seelos Therapeutics' (SEEL) postponed Annual Meeting?
How can stockholders participate in Seelos Therapeutics' (SEEL) postponed Annual Meeting?
